Clinical trial NCT05667701: Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study
Official title: Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Wheezing
Asthma in Children
Keywords: wheezing
soy isoflavone
PAI-1
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Sponsor class: OTHER
Collaborators: name: Northwestern University
name: University of South Florida
name: University of Colorado, Denver
name: National Institute of Allergy and Infectious Diseases (NIAID)
First posted: 2022-12-29
Enrollment: 65
Sex: ALL
Minimum age (years): 2
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: genotype stratified, quadruple blinded randomized clinical trial
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to compare soy isoflavones to placebo in children who at risk of asthma and have a genetic variation which results in them making more of a pro-inflammatory protein, plasminogen activator inhibitor-1. The main questions this trail seeks to answer is: will soy isoflavones decrease the proportion of infants with aT2 high endotype at the end of treatment, and secondarily decrease the number of wheezing episodes in these children when given in the first year of life. Participants will be asked to ingest soy isoflavone or placebo twice daily mixed into a liquid or puree vehicle for 7 months from randomization. There will be 3 mandatory in-person visits, and 6 virtual visits in the first year. There will also be 11 monthly questionnaires and 1 in person visit in the observation year. Participants will have 4 nasal swabs, 3 blood draws, and also provide 4 stool samples over the course of the study.

Detailed description: The study is designed as a single site, randomized, quadruple-masked, placebo-controlled, parallel group clinical trial. We will enroll 65 high risk infants with the PAI-1 risk genotype, who are between 0-6.5 months of age, and will be randomized to one of two treatment groups. The treatment groups will be either oral isoflavone supplement (at doses similar to that seen in soy formula) or a matching placebo .

Screening will occur throughout each year, with genotyping occurring at the first visit, and assumption of care of individuals with the risk genotype after randomization. There will be a study run in period up to 6 months at which time subjects will be randomized. The treatment period will run for 7 months for each participant, and will have a 1 year observation period after the end of treatment.

At randomization, the investigators will assume the care of the children for all wheezing illnesses. The subjects will have either virtual or in person visits for each of the next 6 visits, followed by an in-person visit at the end of treatment. The subjects will also come in for in-person visits at times of viral illnesses. At randomization, end of treatment, viral illness, and end of study the subjects will have nasal swabs and nasosorption carried out. Blood draws will occur at randomization, end of treatment, and the end of study visit. Stool will be collected for microbiome assessment at randomization, the 3rd or 4th month of treatment, the end of treatment, and the end of the study at the end of the observation year. The study will also measure infant pulmonary function using a wearable device to assess expiratory variability overnight. This will be measured at randomization, viral illness, end of treatment, and at the end of the study after the 1 year observation period. The treatment period will run for 7 months for each participant, with a 1 year observation period after this.

Eligibility criteria: Inclusion Criteria:

1. Parent guardian must be able to understand and provide informed consent.
2. Age: Term children (≥37 weeks gestational age) born from January 1 to May 15 of the recruitment year.
3. High risk of asthma: As determined by one or more of the following:

   1. A history of uni- or bi-parental asthma with onset in childhood by parent self report, OR
   2. Uni- or bi-parental asthma with onset after childhood along with the presence of one or more other comorbid atopic condition including allergic rhinitis, atopic dermatitis, or food allergy, OR
   3. atopic dermatitis in the child determined by parent report of a physician diagnosis
4. Genotype: Either homozygous or heterozygous for the PAI-1 risk allele (i.e. 4G4G or 4G5G).

Exclusion Criteria:

1. Inability or unwillingness of a parent guardian to give written informed consent or comply with study protocol.
2. Parents who will not include either a puree or some form of bottle feeding such that the infant would be able to take the investigational product in a puree or a liquid (expressed breast milk, supplemental formula, or a small amount of water).
3. Currently on a soy based formula.
4. Breastfeeding mothers who are taking soy supplements or soy enriched foods more than 2 times a week and will not stop this level of ingestion while breastfeeding.
5. On treatment for recurrent wheezing such as regular inhaled steroids.
6. The subject may not have the following specific contraindications: known congenital thyroid disease, or a history of estrogen sensitive clinically relevant mutations in the family (such as BRACA1).
7. Medication use

   1. Maternal use of tamoxifen in pregnancy or if breastfeeding
   2. Use of immunomodulatory medications such at methotrexate, mycophenolate, azathioprine, or other immunomodulatory agent in the mother if breastfeeding or in the infant.
8. Use of another investigational agent in the last 30 days prior to randomization.
9. Current, parent reported, diagnosis of mental illness or current, diagnosed or self-reported drug or alcohol abuse (in the primary caregiver) that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
10. Known allergy to soy protein (either by reported allergy or skin testing to soy prior to randomization) or reported allergy to NovaSoy, from which the investigational product is compounded.
11. The infant is currently participating in another asthma-related pharmaceutical study or intervention study or who have participated in another asthma-related pharmaceutical study or intervention study in the month prior to enrollment.
12. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
13. Any chronic condition requiring use of systemic corticosteroids or another immunomodulating agent at screening or run-in, and during the course of the study
14. Non-adherence:

    1. Inability / unwillingness of the parents to induce the child to swallow study medication
    2. Unwillingness of the parents to allow the staff to perform baseline measurements
15. Living with a foster parent as a ward of the state.
16. Caregiver does not have access to a phone (needed for scheduling appointments or responding to questionnaires);
17. Plan(s) for the family to move from the area during the study period;
18. The participant's caretaker does not primarily speak English or Spanish

Primary outcomes:
measure: T2 endotype
timeFrame: From week 0 (randomization) to week 30 (end of treatment)
Secondary outcomes:
measure: wheezing episodes
timeFrame: 7 months
measure: Expiratory variability index
timeFrame: from week 0 (randomization) to week 30 (end of treatment) and from week 0 (randomization) to week 88 (end of study)
measure: safety and tolerability
timeFrame: from week 0 (randomization) to week 88 (end of study)
Other outcomes:
measure: Other measures of wheezing and respiratory morbidity
timeFrame: week 88 - end of study visit
measure: sensitization to allergens
timeFrame: Week 30 at the end of treatment
measure: work disruption due to child's asthma
timeFrame: Week 0 to week 30
measure: Daycare/ pre-school Absences due to the child's asthma
timeFrame: from randomization (week 0) to the end of treatment (week 30) and secondarily to the end of the observation period (week 88)
Locations:
city: Chicago
country: United States
facility: Ann and Robert H Lurie Childrens Hospital of Chicago
state: Illinois
city: Chicago
country: United States
facility: Northwestern University Feinberg School of Medicine
state: Illinois
Study officials:
affiliation: Ann and Robert H. Lurie Children's Hospital of Chicago
name: Rajesh Kumar, MD
role: PRINCIPAL_INVESTIGATOR
References: